Cordatus Wealth Management LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Cordatus Wealth Management LLC bought a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,260 shares of the medical research company’s stock, valued at approximately $2,153,000.

Other large investors have also added to or reduced their stakes in the company. AMF Tjanstepension AB increased its holdings in shares of Amgen by 16.9% during the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after acquiring an additional 17,387 shares in the last quarter. Swedbank AB increased its holdings in shares of Amgen by 1.1% during the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after acquiring an additional 5,751 shares in the last quarter. Segment Wealth Management LLC increased its holdings in shares of Amgen by 5.6% during the third quarter. Segment Wealth Management LLC now owns 938 shares of the medical research company’s stock valued at $302,000 after acquiring an additional 50 shares in the last quarter. Elevated Capital Advisors LLC increased its holdings in shares of Amgen by 2.5% during the third quarter. Elevated Capital Advisors LLC now owns 1,539 shares of the medical research company’s stock valued at $496,000 after acquiring an additional 38 shares in the last quarter. Finally, Lake Street Private Wealth LLC increased its holdings in shares of Amgen by 10.1% during the third quarter. Lake Street Private Wealth LLC now owns 1,861 shares of the medical research company’s stock valued at $600,000 after acquiring an additional 171 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,405 shares of company stock worth $10,410,596 in the last quarter. Corporate insiders own 0.69% of the company’s stock.

Amgen Trading Up 1.2 %

Shares of NASDAQ:AMGN opened at $297.93 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm has a market capitalization of $160.05 billion, a price-to-earnings ratio of 39.46, a price-to-earnings-growth ratio of 2.54 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The business’s 50 day moving average price is $275.62 and its 200-day moving average price is $300.75.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts forecast that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.20%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Bank of America upped their price objective on shares of Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, UBS Group dropped their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.